Harry Hayter

Harry Hayter has a diverse work experience spanning multiple industries and roles. Harry is currently a Senior Vice President of Business Development at Culmination Bio. Prior to that, they held the position of Senior Vice President of Commercial Development at C2i Genomics. Harry also served as the Director of Key Accounts at GRAIL, Inc. and held various positions at Tempus, Inc., including VP of Commercial Markets and Vice President of Business Development.

Earlier in their career, Hayter worked as the Director of Payer Relations and Reimbursement at Foundation Medicine, National Account Director at United Therapeutics, and National Account Executive and Senior Manager of Reimbursement at Endo Pharmaceuticals. Harry also served as a National Account Manager at both Indevus Pharmaceuticals and Valera Pharmaceuticals.

Hayter began their career as a Regional Account Manager at Takeda Pharmaceuticals, where they later became the National Account Manager (Federal). Harry had additional responsibilities in Medicaid for Utah, Idaho, and Montana.

Harry Hayter attended the University of Montana from 1991 to 1996. No degree or specific field of study is provided.